HONG KONG, NEW JERSEY, 25 June 2025 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce its strategic partnership with Somerset Therapeutics LLC (“Somerset”), a leading American pharmaceutical company for the manufacturing and supplying affordable generic medicines in the US market.

On 29 May 2025, Zhaoke signed a supply and distribution agreement with Somerset. As part of the agreement, Zhaoke will research and develop drugs for the U.S. market and grant exclusive rights to Somerset to apply for the relevant regulatory approvals in the territory. Once regulatory approvals are obtained, Zhaoke will manufacture the drugs and supply to Somerset for the commercialization of these medicines in the U.S.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “The U.S. represents one of the most critical and competitive markets for pharmaceutical innovation, and Zhaoke has strategically prioritized its expansion in the U.S. as part of our global growth vision. Our partnership with Somerset underscores the industry’s recognition in Zhaoke’s world-class R&D expertise and vertically integrated manufacturing capabilities. This marks a significant step in building out our U.S. footprint, and strengthen our brand reputation in the U.S.”

Dr. Veerappan Subramanian, Chairman and Chief Executive Officer of Somerset Therapeutics LLC, commented: “We are pleased to partner with Zhaoke, whose proven scientific and manufacturing capabilities align with Somerset’s commitment to delivering high-quality, accessible medicines to patients across the U.S. healthcare system. With our deep expertise in the generic market, intellectual property, product pipeline, regulatory strategy, and commercialization, Somerset is uniquely positioned to bring impactful therapies to both patients and providers. This collaboration reflects our shared vision for innovation, global reach, and patient-centered care—and we look forward to delivering meaningful healthcare solutions in one of the world’s most dynamic pharmaceutical landscapes.”

About Somerset Therapeutics LLC
Somerset Therapeutics LLC is an American pharmaceutical company founded in 2013 by Dr. Veerappan Subramanian and Dr. Ilango Subramanian, with a mission to develop, manufacture, and commercialize affordable generic medicines across a broad range of therapeutic areas. Serving patients, caregivers, and healthcare providers across the U.S., Somerset has built a strong presence in both the retail and hospital markets.

In just over a decade, Somerset has earned a reputation as a reliable and trusted supplier in the pharmaceutical industry. Our unwavering focus on quality and affordability drives our continued growth. With a robust product pipeline and state-of-the-art manufacturing capabilities, we currently market nearly 75 FDA-approved generic products—ensuring consistent access to safe, effective, and high-quality medicines for patients and providers alike.

For more information, please visit:  www.somersetpharma.com